Home / Academic Researcher / Xilis MicroOrganoSphere
XI
Paid FEATURED

Xilis MicroOrganoSphere

Precision oncology platform using miniature patient replicas.

Uses patient biopsies and AI-driven analysis of miniature organ replicas (MOS) to assess reactions to diverse drugs, enabling the optimal personalized treatment path for cancer.

PROS

  • + Provides functional evidence of drug response
  • + bridging the gap between genomic data and treatment efficacy.
  • + Rapid turnaround time (around 10-14 days) enables timely clinical decision-making.
  • + Replicates the tumor microenvironment
  • + including immune and stromal cells
  • + for higher fidelity testing.
  • + Automated and scalable process for high-throughput
  • + reproducible drug response profiling.

CONS

  • - Relies on the availability and processing of a patient tissue biopsy sample.
  • - A specialized B2B service
  • - requiring partnership or service contract access.
  • - Cost per patient assay
  • - though positioned as cost-effective
  • - may be substantial.
  • Guiding initial therapy selection for cancer patients with functional drug testing
  • Identifying and testing secondary treatment options for patients with drug-resistant or relapsed cancer
  • Accelerating preclinical drug efficacy and toxicity testing in pharmaceutical R&D
  • Providing functional confirmation to increase clinician confidence in treatment decisions

SIMILAR TOOLS

Weekly Intel

STAY AHEAD OF THE AI CURVE

Join 10,000+ professionals getting curated AI tool recommendations. No fluff, just actionable value.